Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: Second interim analysis of data from a phase III, multi- institutional trial

Annals of Surgery

Volumn 226, Issue 2, 1997, Pages 198-206

  Wallack, Marc K ^a   Sivanandham, Muthukumaran ^a   Ditaranto, Kristen ^a   Shaw, Palma ^a   Balch, Charles M ^b   Urist, Marshall M ^b   Bland, Kirby I ^d   Murray, Douglas ^e   Robinson, William A ^f   Flaherty, Lawrence ^g   Richards, Jon M ^h   Rosen, Les ⁱ   Bartolucci, Alfred A ^c  

^a ST VINCENT S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e EMORY UNIVERSITY   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ Miami Heart Inst   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOLIPID; MELANOMA ANTIGEN; PLACEBO; SMALLPOX VACCINE; VACCINIA ONCOLYSATE; VACCINIA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION PAIN; INTRADERMAL DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

ADULT; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SMALLPOX VACCINE; SURVIVAL RATE; VACCINES;

EID: 0031443559     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199708000-00012     Document Type: Article

References (25)

1. Balch CM, Urist MM, Maddox WA, et al. Management of regional metastatic melanoma. In: Balch CM, Milton GW, eds. Cutaneous Melanoma. New York: JB Lippincott; 1985:93-130.
2. McLeod GR. Factors influencing prognosis in malignant melanoma. Progress in Clinical Cancer. 6th ed. New York: Grune & Stratton; 1975; 6:177-182.
3. Morton DL, Foshag LJ, Nizze JA, et al. Active specific immunotherapy in malignant melanoma. Semin Surg Oncol 1989; 5:420-425.
4. Wallack MK, Steplewski A, Koprowski HK, et al. A new approach in specific, active immunotherapy. Cancer 1977; 39:560-564.
5. Hersey P, Edwards A, Coates A, et al. Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Cancer Immunol Immunother 1987; 25:257-265.
6. Mitchell MS, Mitchell JK, Kempf RF, et al. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 1988; 48:5883-5889.
7. Bystryn J, Oratz R, Henn M, et al. Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 1992; 69:1157-1164.
8. Livingston PO, Wong GYC, Adluri S, et al. A randomized trial of adjuvant vaccination with GM2 ganglioside in patients with AJCC Stage III melanoma. Clin Oncol 1994; 12:1036-1044.
9. Mittelman A, Chen Z-J, Kageshita T, et al. Active specific immunotherapy in patients with melanoma: a clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic ami-highmolecular-weight-molenoma-associated antigen monoclonal antibodies. J Clin Invest 1990; 86:2136-2141.
10. Wallack MK. Specific active Immunotherapy with vaccinia oncolysates. In: Crispen R, ed. Tumor Progression. New York: Elsevier, North Holland Inc; 1980:277-287.
11. Lindenmann J, Klein P. Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus. J Exp Med 1967; 126:93-108.
12. Wallack MK, Meyer M, Bourgoin A, et al. A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment. J Biol Response Modifiers 1983; 2:586-596.
13. Wallack MK, McNally KR, Leftheriotis E, et al. A southeastern cancer study group phase I/II trial with vaccinia melanoma oncolysates. Cancer 1986; 57:649-655.
14. Wallack MK, Bash JA, Leftheriotis E, et al. Positive relationship of clinical and serological responses to vaccinia melanoma oncolysate. Arch Surg 1987; 122:1460-1463.
15. Wallack MK, Sivanandham M, Balch CM, et al. A phase III, randomised, double-blind, multi-institutional trial of vaccinia melanoma oncolysate (VMO) active specific immunotherapy for patients with stage II (UICC) melanoma. Cancer 1995; 75:34-42.
16. Wallack MK, Sivanandham M, Whooley B, et al. Favorable clinical responses in subsets of patients from a randomized, multiinstitutional melanoma vaccine trial. Ann Surg Oncol 1996; 3:110-117.
17. International Union Against Cancer (UICC): TNM classification of malignant tumors. 2nd ed. Geneva, Switzerland: UICC, World Health Organization; 1978.
18. Krikwood JM, Strawdermon MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern cooperative oncology group trial EST 1684. J Clin Oncol 1996; 14:7-17.
19. Burdick KH. Malignant melanoma treated with vaccinia injections. Arch Dermatol 1960; 82:438-439.
20. Roenigk HH, Jr, Deodhar S, Jacques RS, et al. Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 1974; 109:668-673.
21. Mitchell MS, Jakowatz J, Harel W, et al. Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma. J Clin Oncol 1194; 12:402-411.
22. Arroyo PJ, Bash JA, Wallack MK. Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects on interleukin-2 and interferon alpha in a murine hepatic metastasis model. Cancer Immunol Immunother 1993; 31:305-311.
23. Tanaka N, Sivanandham M, Wallack MK. Active specific immunotherapy of vaccinia colon oncolysate prepared with IL-2 gene encoded vaccinia virus in combination with interferon alpha in a syn- geneic murine colon adenocarcinoma. J Immunother 1994; 16:283-293.
24. Sivanandham M, Tanaku N, Wallack MK. Cytokine encoded recombinant vaccinia virus in the active specific immunotherapy of cancers. Proceeding of the XVI International Cancer Congress, New Delhi, India; 1994:505-509.
25. Sivanandham M, Scoggin SD, Sperry RG, Wallack MK. Therapeutic Effect of Oncolysate prepared with the interleukin-2 gene encoded vaccinia virus: study with the C-C36 murine colon hepatic metastases model. Cancer Immunol Immunother 1994; 38:259-264.